Sarah Aiosa oversees the entire Latin America region for MSD, where the global giant is looking to build on its 100-year legacy by better addressing the continent's health inequities and unmet medical needs. Aiosa describes the myriad public-private partnerships that the firm has struck in LatAm across areas including cancer screening, women's health, and vaccine technology transfer; the importance of clinical trials in the region; and why she is optimistic about the future of LatAm healthcare.
Two LatAm countries – Colombia and Mexico – are [MSD's] top clinical trial patient enrollers worldwide, and LatAm makes up approximately 15 percent of our total active trials
